Pharmaceutical giant AstraZeneca has unveiled a sweeping $50 billion investment plan in the U.S., set to roll out by 2030, in a move that underscores the country’s growing dominance in biopharmaceutical research, development, and advanced manufacturing.
The company’s multibillion-dollar commitment is expected to generate tens of thousands of high-skilled direct and indirect jobs across the U.S., while advancing the development and delivery of next-generation medicines for patients in America and around the world.
At the heart of this investment is a new state-of-the-art manufacturing facility to be built in the Commonwealth of Virginia. Touted as AstraZeneca’s largest-ever single manufacturing investment globally, the plant will produce drug substances for its expanding portfolio of innovative treatments in weight management and metabolic disease, including oral GLP-1 therapies, baxdrostat, oral PCSK9 inhibitors, and combination small molecule products.
Read: 10 biggest companies in the world by market capitalization
The facility will manufacture a range of drug formats, including small molecules, peptides, and oligonucleotides, using cutting-edge technologies such as AI, automation, and data analytics to maximize efficiency and output.
This latest announcement builds on the $3.5 billion investment the company disclosed in November 2024 and represents a major expansion of AstraZeneca’s footprint in the U.S.
Beyond Virginia, the $50 billion investment will support a broad network of initiatives aimed at bolstering both research and production capabilities:
- Gaithersburg, Maryland: Expansion of the company’s R&D campus to accelerate drug discovery and development.
- Kendall Square, Cambridge, Massachusetts: Construction of a new, state-of-the-art research and development center in one of the world’s leading biotech hubs.
- Rockville, Maryland and Tarzana, California: Establishment of new manufacturing facilities dedicated to cell therapy production.
- Mount Vernon, Indiana: Continued investment in expanding pharmaceutical manufacturing operations.
- Coppell, Texas: Growth of specialty drug manufacturing capacity.
AstraZeneca’s commitment further cements the U.S. as a central hub for life sciences innovation and positions the company at the forefront of a rapidly evolving healthcare landscape.
